^
Association details:
| Biomarker: | LRP1B mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune checkpoint inhibitor response in tumors with LRP1B variants.
Excerpt:
The most common ICIs were pembrolizumab (29/44, 66%) and nivolumab (12/44, 27%)....Among pts with LRP1b PVs, 36% (95%CI 14%-64%) had radiographic responses (5/14, 2 lung, 1 prostate, 1 RCC, 1 endometrial carcinoma), two of whom were MSI high....The majority of responders were MSS and TMB low, which may suggest that PV in LRP1B may independently predict for response to ICI.
DOI:
10.1200/JCO.2019.37.15_suppl.e14291
